Paul A Goepfert
Overview
Explore the profile of Paul A Goepfert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
140
Citations
8727
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang B, Fong Y, Dang L, Fintzi J, Chen S, Wang J, et al.
Nat Commun
. 2025 Jan;
16(1):759.
PMID: 39824819
Neutralizing antibody titer has been a surrogate endpoint for guiding COVID-19 vaccine approval and use, although the pandemic's evolution and the introduction of variant-adapted vaccine boosters raise questions as to...
2.
Piepenbrink M, Khalil A, Chang A, Mostafa A, Basu M, Sarkar S, et al.
Npj Viruses
. 2024 Nov;
2(1):55.
PMID: 39553825
SARS-CoV-2 continues to be a public health burden, driven in-part by its continued antigenic diversification and resulting emergence of new variants. By increasing herd immunity, current vaccines have improved infection...
3.
Carpp L, Hyrien O, Fong Y, Benkeser D, Roels S, Stieh D, et al.
Nat Commun
. 2024 Nov;
15(1):9785.
PMID: 39532861
Assessment of immune correlates of severe COVID-19 has been hampered by the low numbers of severe cases in COVID-19 vaccine efficacy (VE) trials. We assess neutralizing and binding antibody levels...
4.
Fong Y, Dang L, Zhang B, Fintzi J, Chen S, Wang J, et al.
Clin Infect Dis
. 2024 Sep;
80(1):223-227.
PMID: 39325506
For COVAIL recipients of a coronavirus disease 2019 (COVID-19) Sanofi booster vaccine, neutralizing antibody titers were assessed as a correlate of risk (CoR) of COVID-19. Peak and exposure-proximal titers were...
5.
Janes H, Fisher L, Kee J, Parameswaran L, Goepfert P, Falsey A, et al.
J Infect Dis
. 2024 Sep;
230(6):1384-1389.
PMID: 39225478
Coronavirus disease 2019 (COVID-19) vaccines reduce severe disease and mortality and may lessen transmission, measured by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load (VL). Evaluating vaccine associations in...
6.
Files J, Goepfert P
Top Antivir Med
. 2024 Aug;
32(2):420-430.
PMID: 39141920
Over the past several years, messenger RNA (mRNA) vaccine has evolved from a term familiar only to vaccine scientists into one easily recognized by much of the general population. This...
7.
Erlandson K, Geng L, Selvaggi C, Thaweethai T, Chen P, Erdmann N, et al.
Ann Intern Med
. 2024 Aug;
177(9):1209-1221.
PMID: 39133923
Background: There are currently no validated clinical biomarkers of postacute sequelae of SARS-CoV-2 infection (PASC). Objective: To investigate clinical laboratory markers of SARS-CoV-2 and PASC. Design: Propensity score-weighted linear regression...
8.
Walsh S, Gay C, Karuna S, Hyrien O, Skalland T, Mayer K, et al.
PLoS Med
. 2024 Jun;
21(6):e1004329.
PMID: 38913710
Background: Broadly neutralizing antibodies (bnAbs) are a promising approach for HIV-1 prevention. In the Antibody Mediated Prevention (AMP) trials, a CD4-binding site targeting bnAb, VRC01, administered intravenously (IV), demonstrated 75%...
9.
Fisher L, Kee J, Liu A, Espinosa C, Randhawa A, Ludwig J, et al.
JAMA Netw Open
. 2024 May;
7(5):e2412835.
PMID: 38780941
Importance: SARS-CoV-2 viral load (VL) in the nasopharynx is difficult to quantify and standardize across settings, but it may inform transmission potential and disease severity. Objective: To characterize VL at...
10.
Piepenbrink M, Khalil A, Chang A, Mostafa A, Basu M, Sarkar S, et al.
bioRxiv
. 2024 May;
PMID: 38746414
SARS-CoV-2 continues to be a public health burden, driven in-part by its continued antigenic diversification and resulting emergence of new variants. While increasing herd immunity, current vaccines, and therapeutics have...